Advanced search
Publication Cover
Journal of Medical Economics Volume 14, 2011 - Issue 2
Submit an article Journal homepage
572
Views
10
CrossRef citations to date
0
Altmetric
Original Article

Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States

Michael S. Broder Partnership for Health Analytic Research, Beverly Hills, CA, USACorrespondence[email protected]
,
Eunice Y. Chang Partnership for Health Analytic Research, Beverly Hills, CA, USA
,
Tanya G.K. Bentley Partnership for Health Analytic Research, Beverly Hills, CA, USA
,
Timothy Juday Bristol-Myers Squibb, Plainsboro, NJ, USA
&
Jonathan Uy Bristol-Myers Squibb, Plainsboro, NJ, USA
Pages 167-178 | Accepted 12 Jan 2011, Published online: 24 Mar 2011

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

K. N. Simpson, R. W. Baran, D. Collomb, E. J. Beck, O. Van de Steen & B. Dietz. (2012) Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011. Journal of Medical Economics 15:4, pages 796-806.
Read now

Articles from other publishers (9)

David WambleMichael CiarametaroKatherine HoughtonMayank AjmeraRobert W. Dubois. (2019) What’s Been The Bang For The Buck? Cost-Effectiveness Of Health Care Spending Across Selected Conditions In The US. Health Affairs 38:1, pages 68-75.
Crossref
Richard E. NelsonJunjie MaJacob CrookKristin KnippenbergHeather NymanDamemarie PaulStephen EskerJoanne LaFleur. (2018) Health Care Costs in a Cohort of HIV-Infected U.S. Veterans Receiving Regimens Containing Tenofovir Disoproxil Fumarate/Emtricitabine. Journal of Managed Care & Specialty Pharmacy 24:10, pages 1052-1066.
Crossref
José Moltó, Javier A. Estévez, Cristina Miranda, Samandhy Cedeño, Bonaventura Clotet & Marta Valle. (2016) Population pharmacokinetic modelling of the changes in atazanavir plasma clearance caused by ritonavir plasma concentrations in HIV-1 infected patients. British Journal of Clinical Pharmacology 82:6, pages 1528-1538.
Crossref
E Wilkins, M Fisher, AJ Brogan, SE Talbird & EM La. (2015) Cost‐effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment‐naïve adults with HIV ‐1 infection in the UK , based on the AIDS Clinical Trials Group 5202 clinical trial . HIV Medicine 17:7, pages 505-515.
Crossref
Barent N. DuBois, Jessica Atrio, Frank Z. Stanczyk & Ganesh Cherala. (2015) Increased exposure of norethindrone in HIV+ women treated with ritonavir-boosted atazanavir therapy. Contraception 91:1, pages 71-75.
Crossref
Paola Codella, Silvia Coretti, Alessandra Fiore, Giuliano Rizzardini & Matteo Ruggeri. (2014) Cost-Effectiveness Studies in HIV Treatment with Lopinavir/Ritonavir: A Review. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish 1:2, pages GRHTA.5000184.
Crossref
Josephine Mauskopf. (2013) A Methodological Review of Models Used to Estimate the Cost Effectiveness of Antiretroviral Regimens for the Treatment of HIV Infection. PharmacoEconomics 31:11, pages 1031-1050.
Crossref
Emanuela Foglia, Paolo Bonfanti, Giuliano Rizzardini, Erminio Bonizzoni, Umberto Restelli, Elena Ricci, Emanuele Porazzi, Francesca Scolari & Davide Croce. (2013) Cost-Utility Analysis of Lopinavir/Ritonavir versus Atazanavir + Ritonavir Administered as First-Line Therapy for the Treatment of HIV Infection in Italy: From Randomised Trial to Real World. PLoS ONE 8:2, pages e57777.
Crossref
Upal Roy, JoEllyn McMillan, Yazen Alnouti, Nagsen Gautum, Nathan Smith, Shantanu Balkundi, Prasanta Dash, Santhi Gorantla, Andrea Martinez-Skinner, Jane Meza, Georgette Kanmogne, Susan Swindells, Samuel M. Cohen, R. Lee Mosley, Larisa Poluektova & Howard E. Gendelman. (2012) Pharmacodynamic and Antiretroviral Activities of Combination Nanoformulated Antiretrovirals in HIV-1–Infected Human Peripheral Blood Lymphocyte–Reconstituted Mice. The Journal of Infectious Diseases 206:10, pages 1577-1588.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.